Pharvaris N.V. (PHVS)
NASDAQ: PHVS · Real-Time Price · USD
25.42
-0.96 (-3.64%)
At close: Mar 13, 2026, 4:00 PM EDT
25.35
-0.07 (-0.28%)
After-hours: Mar 13, 2026, 7:27 PM EDT
Pharvaris Employees
Pharvaris had 118 employees as of September 30, 2025. The number of employees increased by 26 or 28.26% compared to the same quarter last year.
Employees
118
Change
26
Growth
28.26%
Revenue / Employee
n/a
Profits / Employee
-$1,627,893
Market Cap
1.39B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 118 | 26 | 28.26% |
| Jun 30, 2025 | 114 | 31 | 37.35% |
| Mar 31, 2025 | 119 | 36 | 43.37% |
| Dec 31, 2024 | 108 | 26 | 31.71% |
| Sep 30, 2024 | 92 | 22 | 31.43% |
| Jun 30, 2024 | 83 | 15 | 22.06% |
| Mar 31, 2024 | 83 | 17 | 25.76% |
| Dec 31, 2023 | 82 | 17 | 26.15% |
| Sep 30, 2023 | 70 | 14 | 25.00% |
| Jun 30, 2023 | 68 | 21 | 44.68% |
| Mar 31, 2023 | 66 | 25 | 60.98% |
| Dec 31, 2022 | 65 | 31 | 91.18% |
| Sep 30, 2022 | 56 | 39 | 229.41% |
| Jun 30, 2022 | 47 | 30 | 176.47% |
| Mar 31, 2022 | 41 | 27 | 192.86% |
| Dec 31, 2021 | 34 | 20 | 142.86% |
| Jun 30, 2021 | 17 | - | - |
| Mar 31, 2021 | 14 | 11 | 366.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Iovance Biotherapeutics | 975 |
| Sarepta Therapeutics | 835 |
| Novavax | 749 |
| Recursion Pharmaceuticals | 600 |
| Vericel | 398 |
| Zymeworks | 264 |
| Capricor Therapeutics | 160 |
| Innoviva | 159 |
PHVS News
- 3 days ago - Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology - GlobeNewsWire
- 12 days ago - Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026 - GlobeNewsWire
- 4 weeks ago - Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting - GlobeNewsWire
- 2 months ago - Pharvaris Outlines 2026 Strategic Priorities - GlobeNewsWire
- 3 months ago - Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary Angioedema Transcript - Seeking Alpha
- 3 months ago - Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows - Benzinga
- 3 months ago - Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks - GlobeNewsWire
- 3 months ago - Pharvaris: Biotech With De-Risked Phase 3 Readout Coming, Initiating With A Buy Rating - Seeking Alpha